Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. BAX
BAX logo

BAX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
18.260
Open
17.505
VWAP
17.82
Vol
8.01M
Mkt Cap
8.98B
Low
17.290
Amount
142.65M
EV/EBITDA(TTM)
9.77
Total Shares
514.49M
EV
16.47B
EV/OCF(TTM)
17.31
P/S(TTM)
0.80
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
Show More

Events Timeline

(ET)
2026-02-12
16:20:00
Dow Jones Falls 669.42 Points, Nasdaq Drops 469.32 Points
select
2026-02-12
12:20:00
Dow Jones Index Falls 1.10% Amid Technology Profit Concerns
select
2026-02-12
09:00:00
Futures Modestly Higher, S&P 500 Futures Up 0.42%
select

News

Barron's
8.0
18:20 PMBarron's
9 Dividend Stocks to Weather an Oil Crisis
  • Crude Prices and Market Impact: Crude prices are rising significantly, leading to a decline in stock values, prompting investors to seek safer investment options.
  • Stock Sensitivity to Oil Shocks: Not all stocks react the same way to fluctuations in oil prices, indicating that some may offer more stability during these market changes.
CNBC
8.5
03-10CNBC
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
  • Successful Drug Trial: Vertex Pharmaceuticals' experimental drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, reducing levels of a disease marker by 52%, surpassing analyst expectations and indicating significant potential for expansion into kidney diseases.
  • Positive Stock Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting market optimism regarding the prospects of its new drug development, which could provide a new revenue stream for the company.
  • Future Revenue Expectations: Analyst Carter Gould from Cantor Fitzgerald predicts that the two drugs Vertex is developing alongside povetacicept could generate over $10 billion in annual revenue, potentially rivaling the company's cystic fibrosis franchise that generated over $11 billion in sales last year.
  • FDA Application Plans: Vertex plans to submit its application for povetacicept for IgAN to the U.S. FDA by the end of this month, with approval possible later this year through a priority review voucher, further solidifying the company's strategy in the kidney disease market.
NASDAQ.COM
8.5
02-17NASDAQ.COM
Pale Fire Capital Acquires Baxter Shares Worth $39.63 Million
  • New Stake Acquisition: Pale Fire Capital disclosed in its SEC filing dated February 13, 2026, that it acquired 2,074,016 shares of Baxter International, with an estimated trade value of $39.63 million, indicating a strong confidence in the healthcare sector.
  • Position Value Change: At quarter-end, Baxter's position was valued at $39.63 million, reflecting the dual impact of new share acquisitions and stock price movements, further solidifying its place in the investment portfolio.
  • Portfolio Restructuring: Pale Fire Capital significantly increased its investment in healthcare stocks during the fourth quarter, with Baxter being the largest new stock addition, demonstrating a strategic pivot towards the healthcare industry.
  • Sales Growth Potential: Despite reporting significant net losses in 2024 and 2025, Baxter's fourth-quarter sales rose by 8% year-over-year, particularly strong in international markets, indicating potential for future recovery.
Fool
8.5
02-16Fool
Pale Fire Capital Acquires Baxter International Shares
  • New Investment Dynamics: According to its latest SEC filing dated February 13, 2026, Pale Fire Capital SE initiated a new position in Baxter International (BAX) by purchasing 2,074,016 shares, with an estimated transaction value of $39.63 million, reflecting confidence in the healthcare sector.
  • Asset Allocation Shift: Baxter's shares account for 2.66% of Pale Fire Capital SE's $1.49 billion reportable U.S. equity AUM as of December 31, 2025, indicating a strategic focus on healthcare investments by the fund.
  • Market Performance Analysis: As of February 13, 2026, Baxter's stock price stood at $19.79, down 34.2% year-over-year, significantly underperforming the S&P 500 by 46 percentage points, suggesting market caution regarding its future growth prospects.
  • Financial Overview: Baxter reported $11.24 billion in trailing twelve-month revenue and a net loss of $900 million; however, the 8% growth in fourth-quarter sales from continuing operations, particularly in international markets, indicates potential recovery signs.
NASDAQ.COM
4.5
02-13NASDAQ.COM
U.S. Stocks Plunge as Tech Sector Weighs Down Market
  • Tech Sector Retreat: U.S. stocks experienced a significant decline on Thursday, with the S&P 500 down 1.57%, the Dow Jones down 1.34%, and the Nasdaq 100 down 2.04%, primarily driven by a sell-off in the Magnificent Seven tech stocks, indicating concerns over the profitability outlook in the tech sector.
  • Cisco Systems Warning: Cisco Systems saw its stock plummet over 12% after forecasting that rising memory chip prices would erode profitability, raising investor concerns about future performance and potentially diminishing market confidence.
  • Weak Economic Data: Initial jobless claims in the U.S. fell by 5,000 to 227,000, below the expected 223,000, while January existing home sales dropped 8.4% month-over-month to 3.91 million, marking a 16-month low, which reflects signs of economic slowdown that could impact market sentiment.
  • Positive Earnings Season: Despite the overall market downturn, over 76% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings projected to grow by 8.4%, indicating strong corporate profitability that may provide support for the market.
Fool
9.5
02-12Fool
Baxter International Shares Plunge 17% Following Lackluster Earnings Report
  • Disappointing Earnings: Baxter International's Q4 2025 sales rose 8% year-over-year to $2.97 billion, yet its non-GAAP net income plummeted 24% to $225 million ($0.44 per share), failing to meet analysts' expectations of $0.54 per share, resulting in a 17% drop in stock price during trading.
  • Market Reaction: The disappointing earnings report led to a significant decline in Baxter's stock price, which currently stands at $18.79, with a market cap of $11 billion, indicating investor concerns regarding the company's future performance.
  • Bleak Outlook: Baxter forecasts flat to 1% sales growth for 2026, with adjusted net income projected at $1.85 to $2.05 per share, down from $2.27 in 2025, highlighting the challenges and uncertainties the company faces moving forward.
  • Strategic Transition Risks: Although Baxter has pledged to enhance customer relationships and execution through a new operating model, investor skepticism about the long-term effectiveness of this transition may undermine shareholder confidence and future investment decisions.
Wall Street analysts forecast BAX stock price to rise
8 Analyst Rating
Wall Street analysts forecast BAX stock price to rise
2 Buy
5 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
15.00
Averages
22.13
High
30.00
Current: 0.000
sliders
Low
15.00
Averages
22.13
High
30.00
Citi
Neutral
downgrade
$21 -> $19
AI Analysis
2026-03-11
New
Reason
Citi
Price Target
$21 -> $19
AI Analysis
2026-03-11
New
downgrade
Neutral
Reason
Citi lowered the firm's price target on Baxter to $19 from $21 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain "healthy" despite the recent volatility, the analyst tells investors in a research note. Citi's top picks are iRhythm and Medtronic.
Goldman Sachs
Neutral
downgrade
$21 -> $17
2026-02-17
Reason
Goldman Sachs
Price Target
$21 -> $17
2026-02-17
downgrade
Neutral
Reason
Goldman Sachs lowered the firm's price target on Baxter to $17 from $21 and keeps a Neutral rating on the shares. The company's results and 2026 outlook generally fell short of estimates as margin pressures and higher non-operating items drove 2026 EPS guidance mid-point 16% below pre-Q4 consensus, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BAX
Unlock Now

Valuation Metrics

The current forward P/E ratio for Baxter International Inc (BAX.N) is 8.86, compared to its 5-year average forward P/E of 15.38. For a more detailed relative valuation and DCF analysis to assess Baxter International Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
15.38
Current PE
8.86
Overvalued PE
19.52
Undervalued PE
11.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.84
Current EV/EBITDA
9.08
Overvalued EV/EBITDA
13.82
Undervalued EV/EBITDA
9.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.79
Current PS
0.90
Overvalued PS
2.51
Undervalued PS
1.07

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what's a good day trade today
Intellectia · 119 candidates
Price: $5.00 - $80.00Rsi Category: moderatePrice Change Pct: $4.00 - $20.00Relative Vol: >= 1.80List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
AAL logo
AAL
American Airlines Group Inc
9.40B
SMCI logo
SMCI
Super Micro Computer Inc
17.40B
CMCSA logo
CMCSA
Comcast Corp
107.79B
HPQ logo
HPQ
HP Inc
17.23B
GPK logo
GPK
Graphic Packaging Holding Co
3.60B
JBLU logo
JBLU
JetBlue Airways Corp
2.05B
health care
Intellectia · 10 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Sector: Healthcare, Healthcare Services & EquipmentPe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
UNH logo
UNH
UnitedHealth Group Inc
315.01B
NVS logo
NVS
Novartis AG
278.44B
NVO logo
NVO
Novo Nordisk A/S
263.42B
GILD logo
GILD
Gilead Sciences Inc
160.18B
PFE logo
PFE
Pfizer Inc
147.20B
ELV logo
ELV
Elevance Health Inc
82.20B
what healthcare stocks should i buy
Intellectia · 10 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Sector: Healthcare, Healthcare Services & EquipmentPe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
UNH logo
UNH
UnitedHealth Group Inc
315.01B
NVS logo
NVS
Novartis AG
278.44B
NVO logo
NVO
Novo Nordisk A/S
263.42B
GILD logo
GILD
Gilead Sciences Inc
160.18B
PFE logo
PFE
Pfizer Inc
147.20B
ELV logo
ELV
Elevance Health Inc
82.20B
find similar stocks of hims and hers
Intellectia · 208 candidates
Market Cap: 300.00M - 15.00BPs Ratio: <= 15.00Is Optionable: TrueAnnual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GH logo
GH
Guardant Health Inc
14.98B
ICLR logo
ICLR
ICON PLC
14.12B
PEN logo
PEN
Penumbra Inc
14.03B
SOLV logo
SOLV
Solventum Corp
13.94B
SNN logo
SNN
Smith & Nephew PLC
13.91B
NBIX logo
NBIX
Neurocrine Biosciences Inc
13.50B
best medical 3 stocks to buy under $20
Intellectia · 22 candidates
Market Cap: >= 500.00MPrice: <= $20.00Beta: LowRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
HLN logo
HLN
Haleon PLC
45.60B
KVUE logo
KVUE
Kenvue Inc
33.30B
VTRS logo
VTRS
Viatris Inc
15.03B
RDY logo
RDY
Dr Reddy's Laboratories Ltd
11.06B
BAX logo
BAX
Baxter International Inc
10.13B

Whales Holding BAX

T
Thompson, Siegel & Walmsley LLC
Holding
BAX
+4.66%
3M Return
A
ARGA Investment Management, LLC
Holding
BAX
+3.42%
3M Return
E
Equity Investment Corporation
Holding
BAX
+2.62%
3M Return
G
Greenhaven Associates Inc
Holding
BAX
-3.62%
3M Return
P
Pzena Investment Management, Inc.
Holding
BAX
-7.48%
3M Return
M
MIV Asset Management AG
Holding
BAX
-9.35%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Baxter International Inc (BAX) stock price today?

The current price of BAX is 17.905 USD — it has increased 2.55

What is Baxter International Inc (BAX)'s business?

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

What is the price predicton of BAX Stock?

Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is22.13 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Baxter International Inc (BAX)'s revenue for the last quarter?

Baxter International Inc revenue for the last quarter amounts to 2.97B USD, increased 8.03

What is Baxter International Inc (BAX)'s earnings per share (EPS) for the last quarter?

Baxter International Inc. EPS for the last quarter amounts to -2.20 USD, increased 120.00

How many employees does Baxter International Inc (BAX). have?

Baxter International Inc (BAX) has 37500 emplpoyees as of March 11 2026.

What is Baxter International Inc (BAX) market cap?

Today BAX has the market capitalization of 8.98B USD.